DOCSLIB.ORG

Lhx2 Regulates Bone Remodeling in Mice by Modulating RANKL Signaling in Osteoclasts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lhx2 Regulates Bone Remodeling in Mice by Modulating RANKL Signaling in Osteoclasts Cell Death and Differentiation (2014) 21, 1613–1621 & 2014 Macmillan Publishers Limited All rights reserved 1350-9047/14 www.nature.com/cdd Lhx2 regulates bone remodeling in mice by modulating RANKL signaling in osteoclasts JH Kim1,2,3, BU Youn1,2, K Kim1,2, JB Moon1,2, J Lee1,2, K-Il Nam4, Y-W Park5, DDM O’Leary6, KK Kim1,2,3 and N Kim*,1,2,3 The LIM homeobox 2 (Lhx2) transcription factor Lhx2 has a variety of functions, including neural induction, morphogenesis, and hematopoiesis. Here we show the involvement of Lhx2 in osteoclast differentiation. Lhx2 was strongly expressed in osteoclast precursor cells but its expression was significantly reduced during receptor activator of nuclear factor-jB ligand (RANKL)- mediated osteoclastogenesis. Overexpression of Lhx2 in bone marrow-derived monocyte/macrophage lineage cells (BMMs), which are osteoclast precursor cells, attenuated RANKL-induced osteoclast differentiation by inhibiting the induction of nuclear factor of activated T cells c1 (NFATc1). Interestingly, interaction of Lhx2 proteins with c-Fos attenuated the DNA-binding ability of c-Fos and thereby inhibited the transactivation of NFATc1. Furthermore, Lhx2 conditional knockout mice exhibited an osteoporotic bone phenotype, which was related with increased osteoclast formation in vivo. Taken together, our results suggest that Lhx2 acts as a negative regulator of osteoclast formation in vitro and in vivo. The anti-osteoclastogenic effect of Lhx2 may be useful for developing a therapeutic strategy for bone disease. Cell Death and Differentiation (2014) 21, 1613–1621; doi:10.1038/cdd.2014.71; published online 6 June 2014 Bone homeostasis is maintained by a delicate balance PU.1, and nuclear factor of activated T cells c1 (NFATc1), between the activities of osteoblasts and those of osteoclasts. which have a critical role in osteoclastogenesis. Excessive osteoclast activity relative to osteoblast activity c-Fos, a member of the AP-1 family of transcription factors, leads to bone diseases such as osteoporosis.1 Osteoblasts is induced by RANKL in the early stage of osteoclast are mononuclear cells that are responsible for bone formation differentiation. c-Fos knockout mice exhibit an osteopetrotic and osteoclast differentiation. Osteoblasts differentiate from bone phenotype because of defects in the commitment of the mesenchymal progenitors under the control of various growth osteoclast lineage.4,5 Overexpression of c-Fos or NFATc1 in factors, in particular, the bone morphogenetic proteins osteoclast precursor cells lacking c-Fos rescues the osteo- (BMPs).2 clast differentiation defect.6 RANKL activates c-Fos, NF-kB, Osteoclasts are unique bone cells that can control the and a sustained low-amplitude calcium oscillation, which amount of bone tissue by resorbing mineralized bone matrix. results in the induction and activation of NFATc1. Subse- Osteoclasts are characterized by tartrate-resistant acid quently, activated NFATc1 induces the expression of target phosphatase (TRAP)-positive multinuclear cells (MNCs) genes, including TRAP, cathepsin K, and osteoclast-asso- originate from hematopoietic precursors. Osteoclast forma- ciated receptor (OSCAR), which are important for osteoclast tion requires two essential cytokines: macrophage colony- differentiation or function.4,7,8 NFATc1-deficient embryonic stimulating factor (M-CSF) and receptor activator of nuclear stem cells fail to differentiate into osteoclasts in response to factor kB ligand (RANKL). These membrane-bound proteins RANKL.4 In addition, osteoclast-specific conditional NFATc1- are produced by stromal cells and osteoblasts. Binding of deficient mice, which were generated to overcome the M-CSF to its transmembrane receptor c-Fms induces embryonic lethality of NFATc1 knockout mice, develop receptor activation of nuclear kB (RANK) expression on osteopetrosis as a result of the defect in osteoclastogenesis.9 osteoclast precursor cells by activating the Ets transcription Therefore, it has been well established that the RANKL/c-Fos/ factor PU.1 and thereby mediates the proliferation and NFATc1 signaling pathway is the critical converging pathway survival of osteoclasts.3 Binding of RANKL to its receptor for osteoclast differentiation via induction of various osteo- RANK activates various transcription factors, including c-Fos, clast marker genes such as TRAP, cathepsin K, and OSCAR. 1Medical Research Center for Gene Regulation, Chonnam National University Medical School, Gwangju, Republic of Korea; 2Department of Pharmacology, Chonnam National University Medical School, Gwangju, Republic of Korea; 3Center for Creative Biomedical Scientists at Chonnam National University, Chonnam National University Medical School, Gwangju, Republic of Korea; 4Department of Anatomy, Chonnam National University Medical School, Gwangju, Republic of Korea; 5Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea and 6Molecular Neurobiology Laboratory, Salk Institute, La Jolla, CA, USA *Corresponding author: N Kim, Department of Pharmacology, Chonnam National University Medical School, Gwangju 501-746, Republic of Korea. Tel: þ 82 62 220 4418; Fax: þ 82 62 223 4018; E-mail: [email protected] Abbreviations: RANKL, receptor activator of nuclear factor-kB ligand; 1,25(OH)2D3,1a,25-dihydroxyvitamin D3; BMP, bone morphogenetic protein; ALP, alkaline phosphatase; TRAP, tartrate-resistant acid phosphate; M-CSF, macrophage colony-stimulating factor; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinase; NFAT, nuclear factor of activated T cells; TNF, tumor necrosis factor; IFN, interferon; IL-6, interleukin-6; OSCAR, osteoclast-associated receptor; OPG, osteoprotegerin; BMM, bone marrow-derived macrophage lineage cell; ChIP, chromatin immunoprecipitation; Lhx2, LIM homeobox 2; NFATc1, nuclear factor of activated T cells c1; MNC, multinuclear cell; EMSA, electrophoretic mobility shift assay Received 08.11.13; revised 28.4.14; accepted 29.4.14; Edited by JP Medema; published online 06.6.14 The role of Lhx2 in RANKL-induced osteoclastogenesis JH Kim et al 1614 The LIM homeobox 2 transcription factor Lhx2 (also known as LH2 or LH2A) is a member of the LIM homeodomain family of proteins. Members of the LIM-homeodomain family are made of a homeodomain and two LIM domains that comprise two zinc-finger-like structures. The LIM domain can associate with various transcriptional cofactors and may modulate the biological functions of LIM-homeodomain proteins.10 Lhx2 was originally identified in pituitary cells and in pre-B-cell lines.11,12 Lhx2 expression is essential in a wide variety of progenitor/stem cell populations.13 Recent studies have shown that Lhx2 has important roles in eye development, liver differentiation, hair formation, and the complete devel- opment of olfactory sensory neurons.14–16 In this study, we conducted a microarray analysis to find new regulatory molecules that may act as negative regulators during osteoclastogenesis. As a result of the microarray analysis, we found that Lhx2 expression is strongly down- regulated during osteoclast differentiation. Overexpression of Lhx2 in bone marrow-derived monocyte/macrophage lineage cells (BMMs) inhibits RANKL-mediated osteoclastogenesis by inhibiting binding of c-Fos to the promoter of NFATc1, which suggests that Lhx2 acts as a negative regulatory molecule during RANKL-mediated osteoclastogenesis. Furthermore, our results from osteoclast-specific deletion of Lhx2 clearly established that Lhx2 can control bone mass by regulating osteoclast differentiation in vivo. Figure 1 Expression of Lhx2 in osteoclasts and osteoblasts. (a) BMMs were cultured with M-CSF and RANKL for the indicated times. (b) Osteoblasts were cultured with osteogenic medium containing BMP2, ascorbic acid, and Results b-glycerophosphate for the indicated times. (a and b) Quantitative real-time PCR was performed for mRNA expression of NFATc1, TRAP, Lhx2, ALP, and bone Lhx2 expression is downregulated by RANKL during sialoprotein (BSP). Data represent means±S.Ds. *Po0.01, **Po0.001 versus osteoclast differentiation. To examine the expression control patterns of Lhx2, we performed real-time PCR in osteoclasts and osteoblasts. Osteoclast differentiation was induced by containing BMP2, ascorbic acid, and b-glycerophosphate. culturing BMMs in the presence of M-CSF and RANKL. Lhx2 The expression of osteoblast marker genes including alkaline expression was strongly downregulated by RANKL during phosphatase (ALP) and bone sialoprotein was strongly osteoclast differentiation, whereas the expression of NFATc1 increased during osteoblast differentiation, whereas Lhx2 and TRAP, markers for osteoclasts, increased as the cells expression was slightly increased (Figure 1b). differentiated (Figure 1a). Because Lhx2 is downregulated by RANKL at the early stage of osteoclastogenesis, we Overexpression of Lhx2 in osteoclast precursor cells determined which signaling pathways are essential for Lhx2 inhibits RANKL-induced osteoclast formation. To inves- downregulation by using various inhibitors of early signaling tigate the role of Lhx2 in osteoclasts and osteoblasts, we pathways activated by RANKL. As shown in Supplementary overexpressed Lhx2 in BMMs and primary calvarial cells by Figure 1, treatment with SB203580 (p38 MAPK inhibitor), using retrovirus. Transduced BMMs were cultured with PD98059 (MEK inhibitor), and SP600125 (c-Jun N-terminal M-CSF alone or M-CSF and RANKL and stained for TRAP. kinase (JNK) inhibitor) in BMMs did
Load more

Recommended publications
  • Accompanies CD8 T Cell Effector Function Global DNA Methylation
    Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer, Benjamin G. Barwick, Benjamin A. Youngblood, Rafi Ahmed and Jeremy M. Boss This information is current as of October 1, 2021. J Immunol 2013; 191:3419-3429; Prepublished online 16 August 2013; doi: 10.4049/jimmunol.1301395 http://www.jimmunol.org/content/191/6/3419 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130139 Material 5.DC1 References This article cites 81 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/191/6/3419.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 1, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function Christopher D. Scharer,* Benjamin G. Barwick,* Benjamin A. Youngblood,*,† Rafi Ahmed,*,† and Jeremy M.
    [Show full text]
  • Blimp1-Mediated Repression of Negative Regulators Is Required for Osteoclast Differentiation
    Blimp1-mediated repression of negative regulators is required for osteoclast differentiation Keizo Nishikawaa,b, Tomoki Nakashimaa,b,c, Mikihito Hayashia,b, Takanobu Fukunagaa,b, Shigeaki Katod,e, Tatsuhiko Kodamaf, Satoru Takahashig, Kathryn Calameh, and Hiroshi Takayanagia,b,c,1 aDepartment of Cell Signaling, Tokyo Medical and Dental University, Tokyo 113-8549, Japan; bGlobal Center of Excellence Program, International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo 113-8549, Japan; cTakayanagi Osteonetwork Project, Exploratory Research for Advanced Technology, Japan Science and Technology Agency, Tokyo 113-8549, Japan; dInstitute of Molecular and Cellular Biosciences, Graduate School of Medicine, University of Tokyo, Tokyo 113-0032, Japan; eKato Nuclear Complex, Exploratory Research for Advanced Technology, Japan Science and Technology Agency, Saitama 332-0012, Japan; fResearch Center for Advanced Science and Technology, Department of Molecular Biology and Medicine, University of Tokyo, Tokyo 153-8904, Japan; gInstitute of Basic Medical Sciences and Laboratory Animal Resource Center, University of Tsukuba, Tsukuba 305-8575, Japan; and hDepartment of Biochemistry and Molecular Biophysics, Columbia University College of Physicians and Surgeons, New York, NY 10032 Edited by Anjana Rao, Harvard Medical School, Boston, MA, and approved December 23, 2009 (received for review November 7, 2009) Regulation of irreversible cell lineage commitment depends on a own promoter in cooperation with c-Fos (12). This autoampli-
    [Show full text]
  • Gene Expression Profiling of Nfatc1-Knockdown In
    cells Article Gene Expression Profiling of NFATc1-Knockdown in RAW 264.7 Cells: An Alternative Pathway for Macrophage Differentiation Roberta Russo , Selene Mallia, Francesca Zito and Nadia Lampiasi * Institute of Biomedicine and Molecular Immunology “Alberto Monroy”, National Research Council, Via Ugo La Malfa 153, 90146 Palermo, Italy; [email protected] (R.R.); [email protected] (S.M.); [email protected] (F.Z.) * Correspondence: [email protected]; Tel.: +39-091-680-9513 Received: 13 December 2018; Accepted: 5 February 2019; Published: 7 February 2019 Abstract: NFATc1, which is ubiquitous in many cell types, is the master regulator of osteoclastogenesis. However, the molecular mechanisms by which NFATc1 drives its transcriptional program to produce osteoclasts from macrophages (M) remains poorly understood. We performed quantitative PCR (QPCR) arrays and bioinformatic analyses to discover new direct and indirect NFATc1 targets. The results revealed that NFATc1 significantly modified the expression of 55 genes in untransfected cells and 31 genes after NFATc1-knockdown (≥2). Among them, we focused on 19 common genes that showed changes in the PCR arrays between the two groups of cells. Gene Ontology (GO) demonstrated that genes related to cell differentiation and the development process were significantly (p > 0.05) affected by NFATc1-knockdown. Among all the genes analyzed, we focused on GATA2, which was up-regulated in NFATc1-knockdown cells, while its expression was reduced after NFATc1 rescue. Thus, we suggest GATA2 as a new target of NFATc1. Ingenuity Pathway Analysis (IPA) identified up-regulated GATA2 and the STAT family members as principal nodes involved in cell differentiation.
    [Show full text]
  • The Transcriptome of Utricle Hair Cell Regeneration in the Avian Inner Ear
    The Journal of Neuroscience, March 5, 2014 • 34(10):3523–3535 • 3523 Development/Plasticity/Repair The Transcriptome of Utricle Hair Cell Regeneration in the Avian Inner Ear Yuan-Chieh Ku,1 Nicole A. Renaud,1 Rose A. Veile,1 Cynthia Helms,1 Courtney C.J. Voelker,2 Mark E. Warchol,2 and Michael Lovett1 1Department of Genetics and 2Department of Otolaryngology, Washington University School of Medicine, St Louis, Missouri 63110 Sensory hair cell loss is the major cause of hearing and balance disorders. Mammals are incapable of sustained hair cell regeneration, but lower vertebrates can regenerate these mechano-electrical transducers. We present the first comprehensive transcriptome (by mRNA- Seq) of hair cell regeneration in the chick utricle. We provide pathway and pattern annotations and correlate these with the phenotypic events that occur during regeneration. These patterns are surprisingly synchronous and highly punctuated. We show how these patterns are a new resource for identifying components of the hair cell transcriptome and identify 494 new putative hair-cell-specific genes and validate three of these (of three tested) by immunohistochemical staining. We describe many surprising new components and dynamic expression patterns, particularly within NOTCH signaling. For example, we show that HES7 is specifically expressed during utricle hair cell regeneration and closely parallels the expression of HES5. Likewise, the expression of ATOH1 is closely correlated with HEYL and the HLH inhibitory transcription factors ID1, ID2, and ID4.
    [Show full text]
  • Xo PANEL DNA GENE LIST
    xO PANEL DNA GENE LIST ~1700 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes (at 400 -500x average coverage on tumor) Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11
    [Show full text]
  • Nfatc1 As a Therapeutic Target in Burkitt's Lymphoma
    NFATc1 as a Therapeutic Target in Burkitt’s Lymphoma NFATc1 – ein Angriffspunkt zur Therapie des Burkitt-Lymphoms Aus dem Institut für Pathologie der Universität Würzburg Vorstand: Prof. Dr. Andreas Rosenwald Dissertation zur Erlangung der Doktorwürde der Medizinischen Fakultät der Julius-Maximilians-Universität Würzburg vorgelegt von Hendrik Eike Fender Geboren am 6.8.1988 in Göttingen Würzburg, Mai 2015 Referent: Prof. Dr. Dr. Edgar Serfling Korreferent: Prof. Dr. Max Topp Berichterstatter: Prof. Dr. Ralf Bargou Dekan: Prof. Dr. Matthias Frosch Tag der mündlichen Prüfung: 27.4.2016 Der Promovend ist Arzt Abbreviations α anti AICD activation induced cell death AID activation-induced deaminase ATR Ataxia telangiectasia and Rad3 related ATRA all-trans retinoic acid BAFF B cell activation factor of the TNF family BCL6 B-cell lymphoma 6 BCR B cell receptor bHLH basic helix-loop-helix BL Burkitt’s lymphoma BLNK B cell linker Protein Btk Bruton’s tyrosine kinase cAMP cyclic adenosine monophosphate CD cluster of Differentiation CDK cyclin-dependent kinase CK1 α casein kinase 1α CN calcineurin CRAC calcium-release activated calcium CsA cyclosporin A CSR class switch recombination DLBCL diffuse large B cell lymphomas EBV Epstein-Barr-Virus EGTA ethylene glycol tetraacetic acid GC germinal center GM-CSF granulocyte-macrophage colony stimulating factor GSK-3 glycogen synthase kinase 3 Ig immunoglobulin IL interleukin IP3 inositol trisphosphate ITAM immunoreceptor Tyrosine-based Activation Motifs JAK3 Janus kinase 3 mTOR mammalian Target of Rapamycin
    [Show full text]
  • Mafb Negatively Regulates RANKL-Mediated Osteoclast Differentiation
    HEMATOPOIESIS MafB negatively regulates RANKL-mediated osteoclast differentiation Kabsun Kim,1 Jung Ha Kim,1 Junwon Lee,1 Hye Mi Jin,1 Hyun Kook,1 Kyung Keun Kim,1 Soo Young Lee,2 and Nacksung Kim1 1Research Institute of Medical Sciences and Medical Research Center for Gene Regulation, Chonnam National University Medical School, Gwangju, Korea; 2Division of Molecular Life Sciences and Center for Cell Signaling Research, Ewha Womans University, Seoul, Korea Receptor activator of nuclear factor ␬B phage lineage cells (BMMs) inhibits the transactivation of NFATc1 and OSCAR. Fur- ligand (RANKL) induces osteoclast forma- formation of TRAP؉ multinuclear osteo- thermore, reduced expression of MafB by tion from hematopoietic cells via regula- clasts, but phagocytic activity of BMMs is RNAi enhances osteoclastogenesis and tion of various transcription factors. Here, retained. Furthermore, overexpression of increases expression of NFATc1 and we show that MafB negatively regulates MafB in BMMs attenuates the gene induc- OSCAR. Taken together, our results sug- 2020 31 August on guest by https://ashpublications.org/blood/article-pdf/109/8/3253/1291252/zh800807003253.pdf from Downloaded RANKL-induced osteoclast differentia- tion of NFATc1 and osteoclast-associated gest that MafB can act as an important tion. Expression levels of MafB are signifi- receptor (OSCAR) during RANKL-mediated modulator of RANKL-mediated osteoclas- cantly reduced by RANKL during osteo- osteoclastogenesis. In addition, MafB pro- togenesis. (Blood. 2007;109:3253-3259) clastogenesis. Overexpression of MafB teins interfere with the DNA-binding ability in bone marrow-derived monocyte/macro- of c-Fos, Mitf, and NFATc1, inhibiting their © 2007 by The American Society of Hematology Introduction Bone is continuously remodeled by 2 specialized cells: osteoblasts In addition, NFATc1 synergistically induces OSCAR gene expres- and osteoclasts.
    [Show full text]
  • Human Venous Valve Disease Caused by Mutations in FOXC2 and GJC2
    Published Online: 19 July, 2017 | Supp Info: http://doi.org/10.1084/jem.20160875 Downloaded from jem.rupress.org on September 24, 2018 Article Human venous valve disease caused by mutations in FOXC2 and GJC2 Oliver Lyons,1 Prakash Saha,1 Christopher Seet,1 Adam Kuchta,3 Andrew Arnold,3 Steven Grover,4,5 Victoria Rashbrook,1 Amélie Sabine,6,7 Gema Vizcay-Barrena,2 Ash Patel,1 Francesca Ludwinski,1 Soundrie Padayachee,3 Tsutomu Kume,8 Brenda R. Kwak,9 Glen Brice,10 Sahar Mansour,10 Pia Ostergaard,11 Peter Mortimer,11 Steve Jeffery,11 Nigel Brown,12 Taija Makinen,13 Tatiana V. Petrova,6,7 Bijan Modarai,1 and Alberto Smith1 1Academic Department of Vascular Surgery, Cardiovascular Division, BHF Centre of Research Excellence, King’s College London, St Thomas’ Hospital, London, England, UK 2Center for Ultrastructural Imaging, King’s College London, London, England, UK 3Department of Ultrasonic Angiology, Guy’s and St Thomas’ NHS Foundation Trust, London, England, UK 4Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Boston, MA 5Harvard Medical School, Boston, MA 6Department of Fundamental Oncology, Ludwig Institute for Cancer Research, Zurich, Switzerland 7Division of Experimental Pathology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Epalinges, Switzerland 8Feinberg Cardiovascular Research Institute, Northwestern University School of Medicine, Evanston, IL 9Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland 10South West Thames Regional Genetics Service, 11Cardiovascular and Cell Sciences Institute, and 12Institute of Medical and Biomedical Education, St George’s Hospital, London, England, UK 13Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden Venous valves (VVs) prevent venous hypertension and ulceration.
    [Show full text]
  • Identification of Potential Core Genes in Sevoflurance Induced Myocardial
    Identication of Potential core genes in Sevourance induced Myocardial Energy Metabolism in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery using Bioinformatics analysis Hua Lin ( [email protected] ) Tianjin Medical University General Hospital Airport Site Research article Keywords: sevourane, Myocardial Energy Metabolism, Off-pump Coronary Artery Bypass Graft Surgery Posted Date: November 18th, 2019 DOI: https://doi.org/10.21203/rs.2.17434/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/15 Abstract Background: Myocardial ischemia-reperfusion injury always happened after Off-pump coronary artery bypass graft(OPCABG), and this can not be avoided altogether. In this study, we tried to detect potential genes of sevourane-induced myocardial energy metabolism in patients undergoing OPCABG using bioinformatics analysis. Methods: We download and analyze the gene expression prole data from the Gene Expression Omnibus(GEO) database using bioinformatics methods. We downloded the gene expression data from the Gene Expression Omnibus(GEO) database using bioinformatics methods. Gene Ontology(GO) functional annotation analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis were used to analysis the screened differentially expressed genes(DEGs). Then, we established a protein–protein interaction (PPI) network to nd hub genes associated with myocardial energy metabolism. Results: Through PPI network, we nd ten hub genes, including JUN, EGR1, ATF3, FOSB, JUNB, DUSP1, EGR2, NR4A1, BTG2, NR4A2. Conclusions: In conclusion, the proteins encoded by EGR1ATF3c-FosBtg2JunBDUSP1NR4A1BTG2 and NR4A2 were related to cardiac function. ATF3, FOSB, JUNB, DUSP1, NR4A1, NR4A2 are related to apoptosis of cardiomyocytes. The protein encoded by BTG2 is related to hypertrophy.
    [Show full text]
  • Signaling Networks That Control the Lineage Commitment and Differentiation of Bone Cells
    Critical Reviews™ in Eukaryotic Gene Expression, 19(1):1–46 (2009) Signaling Networks that Control the Lineage Commitment and Differentiation of Bone Cells Carrie S. Soltanoff,1 Wei Chen,1,2 Shuying Yang,1,2 & Yi-Ping Li1,2,* 1Department of Cytokine Biology, The Forsyth Institute, Boston, MA 02115, USA; 2Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA 02115, USA * Address all correspondence to Yi-Ping Li, PhD, Department of Cytokine Biology, The Forsyth Institute, 140 The Fenway, Boston, MA 02115; Tel: 617- 892-8260; Fax: 617-262-4021; [email protected] ABSTRACT: Osteoblasts and osteoclasts are the two major bone cells involved in the bone remodeling process. Osteoblasts are responsible for bone formation while osteoclasts are the bone-resorbing cells. The major event that triggers osteogenesis and bone remodeling is the transition of mesenchymal stem cells into differentiating osteoblast cells and monocyte/macrophage precursors into differentiating osteoclasts. Imbalance in differentiation and func- tion of these two cell types will result in skeletal diseases such as osteoporosis, Paget’s disease, rheumatoid arthritis, osteopetrosis, periodontal disease, and bone cancer metastases. Osteoblast and osteoclast commitment and differ- entiation are controlled by complex activities involving signal transduction and transcriptional regulation of gene expression. Recent advances in molecular and genetic studies using gene targeting in mice enable a better understanding of the multiple factors and signaling
    [Show full text]
  • NFAT Signaling and Bone Homeostasis
    & Throm gy b o o l e o t m Journal of Hematology & a b o m Chen and Pan, J Hematol Thromb Dis 2013, 1:1 l e i c H D f DOI: 10.4172/2329-8790.1000102 o i s l e a Thromboembolic Diseases ISSN: 2329-8790 a n s r e u s o J Review Article Open Access NFAT Signaling and Bone Homeostasis Chen S1 and Pan M2* 1Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, P.R. China 2Department of Medical Oncology and Hematology, Kaiser Permanente Medical Center, Santa Clara, CA, USA Abstract Bone homeostasis is a function of the constant balancing acts between osteoclasts and osteoblasts, regulated by numerous factors in cellular and molecular levels. Calcineurin-NFAT pathway plays critical roles in bone homeostasis by regulating many aspects of bone development and remodeling. NFATc1 is the master transcription factor of osteoclasts, acting downstream of RANKL (receptor activator of nuclear factor-κB ligand) to control osteoclastogenesis. NFATc1 also plays important role in osteoblastogenesis, its increased nuclear occupancy in osteoblasts causes osteopetrosis by regulating chemokine and Wnt pathways. Targeting NFAT pathway may provide therapeutic avenues for treating bony disorders. Keywords: Osteoclastogenesis; NFAT; Calcineurin; Osteoblastogen- produce both M-CSF and RANKL to regulate osteoclasts. A single base esis pair insertion of M-CSF receptor gene Csfm in mice is the cause of the recessive mutation osteopetrosis (op) [3]. In human, an activating Regulation of Osteoclasts and Osteoblasts by Key mutation of rank gene and a deactivating mutation of opg (encoded Molecular Networks for osteoprotegerin, OPG) gene cause familiar expansile osteolysis and Paget’s disease of bones [4].
    [Show full text]
  • PDF-Document
    Supplementary Material Investigating the role of microRNA and Transcription Factor co-regulatory networks in Multiple Sclerosis pathogenesis Nicoletta Nuzziello1, Laura Vilardo2, Paride Pelucchi2, Arianna Consiglio1, Sabino Liuni1, Maria Trojano3 and Maria Liguori1* 1National Research Council, Institute of Biomedical Technologies, Bari Unit, Bari, Italy 2National Research Council, Institute of Biomedical Technologies, Segrate Unit, Milan, Italy 3Department of Basic Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy Supplementary Figure S1 Frequencies of GO terms and canonical pathways. (a) Histogram illustrates the GO terms associated to assembled sub-networks. (b) Histogram illustrates the canonical pathways associated to assembled sub-network. a b Legends for Supplementary Tables Supplementary Table S1 List of feedback (FBL) and feed-forward (FFL) loops in miRNA-TF co-regulatory network. Supplementary Table S2 List of significantly (adj p-value < 0.05) GO-term involved in MS. The first column (from the left) listed the GO-term (biological processes) involved in MS. For each functional class, the main attributes (gene count, p-value, adjusted p-value of the enriched terms for multiple testing using the Benjamini correction) have been detailed. In the last column (on the right), we summarized the target genes involved in each enriched GO-term. Supplementary Table S3 List of significantly (adj p-value < 0.05) enriched pathway involved in MS. The first column (from the left) listed the enriched pathway involved in MS. For each pathway, the main attributes (gene count, p-value, adjusted p-value of the enriched terms for multiple testing using the Benjamini correction) have been detailed. In the last column (on the right), we summarized the target genes involved in each enriched pathway.
    [Show full text]